Casdin Capital LLC Has $158.77 Million Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Casdin Capital LLC decreased its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 13.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,040,000 shares of the medical research company’s stock after selling 320,186 shares during the period. Exact Sciences accounts for 4.5% of Casdin Capital LLC’s portfolio, making the stock its 8th largest position. Casdin Capital LLC owned approximately 1.18% of Exact Sciences worth $158,773,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in EXAS. Marshall Wace LLP increased its position in shares of Exact Sciences by 6,721.4% during the third quarter. Marshall Wace LLP now owns 118,420 shares of the medical research company’s stock valued at $11,304,000 after acquiring an additional 116,684 shares in the last quarter. Atria Investments LLC increased its position in shares of Exact Sciences by 35.3% during the third quarter. Atria Investments LLC now owns 11,449 shares of the medical research company’s stock valued at $1,093,000 after acquiring an additional 2,990 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Exact Sciences by 7.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 395,186 shares of the medical research company’s stock valued at $30,756,000 after acquiring an additional 26,058 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of Exact Sciences by 12.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 34,362 shares of the medical research company’s stock valued at $2,674,000 after acquiring an additional 3,772 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp increased its position in shares of Exact Sciences by 65.4% during the third quarter. OMERS ADMINISTRATION Corp now owns 33,676 shares of the medical research company’s stock valued at $3,214,000 after acquiring an additional 13,312 shares in the last quarter. 94.45% of the stock is owned by institutional investors and hedge funds.

EXAS traded up $1.31 on Thursday, reaching $49.74. The stock had a trading volume of 50,914 shares, compared to its average volume of 2,138,024. Exact Sciences Co. has a 12-month low of $46.15 and a 12-month high of $133.99. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.67. The business’s 50-day moving average price is $61.69 and its two-hundred day moving average price is $72.35. The company has a market cap of $8.75 billion, a P/E ratio of -11.21 and a beta of 1.23.

Exact Sciences (NASDAQ:EXAS – Get Rating) last released its quarterly earnings data on Tuesday, April 26th. The medical research company reported ($1.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.08. Exact Sciences had a negative net margin of 40.26% and a negative return on equity of 21.82%. The company had revenue of $486.57 million during the quarter, compared to analysts’ expectations of $461.86 million. During the same quarter in the previous year, the company earned ($0.18) earnings per share. As a group, analysts predict that Exact Sciences Co. will post -4.26 earnings per share for the current year.

In related news, EVP Sarah Condella sold 2,816 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $76.69, for a total transaction of $215,959.04. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider D Scott Coward sold 3,912 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The stock was sold at an average price of $76.69, for a total transaction of $300,011.28. The disclosure for this sale can be found here. Insiders sold 25,077 shares of company stock valued at $1,923,155 in the last ninety days. 1.40% of the stock is owned by corporate insiders.

Several brokerages have recently issued reports on EXAS. Citigroup decreased their target price on shares of Exact Sciences from $80.00 to $65.00 in a research report on Wednesday, April 27th. StockNews.com raised shares of Exact Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, May 15th. Robert W. Baird reduced their price objective on shares of Exact Sciences from $100.00 to $90.00 in a research report on Wednesday, April 27th. SVB Leerink reduced their price objective on shares of Exact Sciences from $140.00 to $130.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 23rd. Finally, The Goldman Sachs Group reduced their price objective on shares of Exact Sciences from $100.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, April 19th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $108.77.

Exact Sciences Company Profile (Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Featured Stories